Avastin Delays Ovarian Cancer Progression
Links shared publicly online about this topic.
- 0total visits
Avastin Delays Ovarian Cancer Progression
View full resource at webmd.com
Tags: Cancer, Cancer Medication, Colorectal Cancer Medication, Ovarian Cancer, Drug, Women's Health, Avastin
Most Recently Shared on December 29, 2011 at 3:39 am By:
Avastin Delays Ovarian Cancer Progression: The cancer drug Avastin helped stop the spread of ovarian cancer in p... http://t.co/acPxJe18
Also Shared By:
Avastin 'delays ovarian cancer growth' | News | Nursing Times
nursingtimes.net — “Women with advanced ovarian cancer may be offered new hope by Avastin’s ability to starve tumours of blood.” View full resource at nursingtimes.net
Most Recently Shared on January 8, 2012 at 12:55 am By:
News: Avastin 'delays ovarian cancer growth' http://t.co/YSTlVihE
Avastin use in ovarian cancer may delay disease - Health - CBC News
cbc.ca — “A drug formerly used to treat advanced breast cancer slightly extend the lifespan of women with advanced ovarian cancer, new research suggests.” View full resource at cbc.ca
Most Recently Shared on December 30, 2011 at 5:56 pm By:
Joanna Lynn CAM and Nutritionist
Avastin use in ovarian cancer may delay disease http://t.co/DmaM2Q59
Medical News: ASCO: Targeted Agent Slows Recurrent Ovarian Cancer - in Meeting Coverage, ASCO from MedPage Today
medpagetoday.com — “CHICAGO -- Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in progression-free survival when bevacizumab (Avastin) was added to chemotherapy, results of a multicenter rand” View full resource at medpagetoday.com
Most Recently Shared on August 29, 2011 at 7:24 pm By:
Roger D. Jones, PhD Health Social Media, PhD, Doctor, and Health Executive
Medical News: ASCO: Targeted Agent Slows Recurrent Ovarian Cancer - http://t.co/DhFILLd from @medpagetoday #health #medicine
Medical News: ASCO: Targeted Agent Slows Recurrent Ovarian Cancer - in Meeting Coverage, ASCO from MedPage Today
medpagetoday.com — “CHICAGO -- Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in progression-free survival when bevacizumab (Avastin) was added to chemotherapy, results of a multicenter rand” View full resource at medpagetoday.com
Most Recently Shared on June 8, 2011 at 10:08 pm By:
ASCO: Targeted Agent Slows Recurrent Ovarian Cancer (with video) http://bit.ly/m03Klj
Roche's Pricy Avastin May Slow Ovarian Cancer Progression
medicalnewstoday.com — “Roche's blockbuster cancer drug Avastin has now additionally been shown to slow the progression of ovarian cancer but does not extend life necessarily according to information presented at this we” View full resource at medicalnewstoday.com
Most Recently Shared on June 6, 2011 at 7:05 pm By:
MNT Ovarian Cancer Health News
Roche's Pricy Avastin May Slow Ovarian Cancer Progression http://mnt.to/3WPr #ovariancancer
Genentech To Present Significant Progress In Advanced Skin, Lung And Ovarian Cancers At ASCO
medicalnewstoday.com — “Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin&” View full resource at medicalnewstoday.com
Most Recently Shared on May 18, 2011 at 3:10 pm By:
Genentech To Present Significant Progress In Advanced Skin, Lung And Ovarian Cancers At ASCO: Genentech, a membe... http://bit.ly/ikFF56
Genentech To Present Significant Progress In Advanced Skin, Lung And Ovarian Cancers At ASCO
medicalnewstoday.com — “Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin&” View full resource at medicalnewstoday.com
Most Recently Shared on May 18, 2011 at 12:05 pm By:
MNT Ovarian Cancer Health News
Genentech To Present Significant Progress In Advanced Skin, Lung And Ovarian Cancers At ASCO http://mnt.to/3W2Y #ovariancancer
UPDATE 1-Roche to present progress in cancer drugs | Reuters
reuters.com — “* To give updates on skin, lung and ovarian cancer drugs * Says skin cancer drug met primary endpoint in phase III * To present positive results on Avastin in ovarian cancer (Adds details, background)” View full resource at reuters.com
Most Recently Shared on May 18, 2011 at 11:15 am By:
John Carroll Health Communicator
Roche says it has promising Ph3 data on vemurafenib for skin cancer , signs of serious side effects, to unveil atASCO.http://reut.rs/jmuzA1
Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO(4)
manufacturing.net — “Progress in advanced skin and lung cancers through personalised healthcare. New Phase III data for Avastin in ovarian cancer to be presented” View full resource at manufacturing.net
Most Recently Shared on May 18, 2011 at 9:52 am By:
Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO(4): Progress in advance... http://bit.ly/lyectS
MicroRNA May Predict Response to Bevacizumab
onclive.com — “The results of a small clinical trial showed that low-level expression of a microRNA correlated with improved progression-free survival” View full resource at onclive.com
Most Recently Shared on April 28, 2011 at 3:01 pm By:
MicroRNA May Predict Response to Bevacizumab (Avastin) in Advanced Ovarian Cancer http://goo.gl/OcVAM
Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint
news-medical.net — “Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.” View full resource at news-medical.net
Most Recently Shared on February 8, 2011 at 9:11 am By:
Lung Cancer News: Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets prima... http://bit.ly/ihU42S
Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint
news-medical.net — “Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.” View full resource at news-medical.net
Most Recently Shared on February 8, 2011 at 9:09 am By:
Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint: Genen... http://bit.ly/eN1Zwe
Bevacizumab Delays Disease Progression in Ovarian Cancer - QualityPoint Technologies
qualitypointtech.net — “Early results from a phase 3 trial add evidence that bevacizumab plus standard therapy reduces the risk for disease progression. Medscape Medical News” View full resource at qualitypointtech.net
Most Recently Shared on October 18, 2010 at 3:17 pm By:
Bevacizumab Delays Disease Progression in Ovarian Cancer: Early results from a phase 3 trial add evidence that bev... http://bit.ly/cxV7tR
Medical News: ESMO: Ovarian CA Responds to Bevacizumab - in Meeting Coverage, ESMO from MedPage Today
medpagetoday.com — “MILAN -- Women with high-risk early or advanced ovarian cancer gained almost two months in progression-free survival (PFS) when the angiogenesis inhibitor bevacizumab (Avastin) was added to chemothera” View full resource at medpagetoday.com
Most Recently Shared on October 13, 2010 at 11:09 pm By:
ESMO: Ovarian CA Responds to Bevacizumab (CME/CE) http://bit.ly/cCiyBY
Advertisement
WebMD_News
@WebMD_News
Avastin Delays Ovarian Cancer Progression: The cancer drug Avastin helped stop the spread of ovarian cancer in p... http://t.co/Vq4DgEeE
1 year ago...